Argos Therapeutics, Inc. (ARGS) Downgraded to Sell at Zacks Investment Research
Argos Therapeutics, Inc. (NASDAQ:ARGS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.
According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “
Separately, FBR & Co cut their target price on Argos Therapeutics from $2.00 to $1.20 and set a “mkt perform” rating on the stock in a report on Wednesday, April 19th. One analyst has rated the stock with a sell rating and three have assigned a hold rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $3.23.
Argos Therapeutics (ARGS) traded up 1.6170% during midday trading on Monday, reaching $0.2388. The company had a trading volume of 1,230,130 shares. The stock has a 50-day moving average price of $0.31 and a 200 day moving average price of $1.13. The company’s market capitalization is $9.87 million. Argos Therapeutics has a 12-month low of $0.23 and a 12-month high of $5.68.
Argos Therapeutics (NASDAQ:ARGS) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.10 million. Argos Therapeutics had a negative return on equity of 1,442.99% and a negative net margin of 12,391.15%. Equities analysts forecast that Argos Therapeutics will post ($1.14) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Argos Therapeutics, Inc. (ARGS) Downgraded to Sell at Zacks Investment Research” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/14/argos-therapeutics-inc-args-downgraded-to-sell-at-zacks-investment-research.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in ARGS. Schwab Charles Investment Management Inc. bought a new position in shares of Argos Therapeutics during the second quarter valued at approximately $137,000. California State Teachers Retirement System bought a new position in shares of Argos Therapeutics during the second quarter valued at approximately $137,000. Geode Capital Management LLC increased its position in shares of Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 3,559 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Argos Therapeutics by 184.5% in the second quarter. Bank of New York Mellon Corp now owns 52,215 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 33,862 shares during the last quarter. Finally, Oxford Asset Management bought a new position in shares of Argos Therapeutics during the second quarter valued at approximately $353,000. 40.35% of the stock is currently owned by hedge funds and other institutional investors.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.